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tumour-reactive CD8+ effectors
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Summary Using peritoneal fluid or pleural effusion obtained from 20 patients with lung. ovanran or
metastatic breast cancer. we separated tumour cells from malignant effusion-associated mononuclear cells
(MEMNCs) using discontinuous Ficoll-Hypaque density gradients. CD3+ T lymphocytes represented the main
population of MEMNCs. The mean ± s.d. CD4 CD8 ratio of MEMNC suspensions was 1.18 ± 0.40.
MEMNCs proliferated and expanded in vitro with human interleukin 2 (IL-2) either as CD13 CD8 cells or as
CD3+CD4+ cells or as mixed populations of CD8+ and CD4+ cells. Preferential cytolytic activity against
autologous tumour cells was demonstrated in IL-2-activated MEMNC cultures with excess CD3 CD8+ cells.
In contrast. effectors derived from IL-2-activated cultures with excess CD3+ CD4+ cells lysed both autologous
and allogeneic tumour target cells. The addition on day 0 of interleukin 1p (IL-1p) to MEMNCs cultured in
the presence of IL-2 was effective in promoting the growth of CD3+ CD8+ cells and augmenting the
cytotoxicity against autologous tumour. Simultaneously. the production of gamma-interferon (IFN-y) was
increased in these cultures. This is the first report suggesting that IL-lp synergises with IL-2 to induce
autologous tumour-specific CD8+ cytotoxic T lymphocytes (CTLs) within the MEMNC population. Selective
enrichment in T-ell subsets by IL-1p may be useful in cellular adoptive immunotherapy using cells isolated
from malignant effusions.
Cytotoxicity against tumour cells is mostly mediated by
natural killer (NK) or lymphokine-activated killer (LAK)
cells and tumour-infiltrating lymphocytes (TILs). In the case
of LAK cells the cytotoxicity is non-major histocompatibility
complex (MHC) restricted. In contrast, the cytotoxicity
exerted by lymphocytes derived from TILs may be MHC
restricted, and such cells possess T-cell characteristics (for a
review see Baxevanis & Papamichail, 1994). Adoptive
immunotherapy in humans with either autologous LAK cells
or TILs expanded in vitro with IL-2 is mostly unsuccessful
since some 60% of patients with metastatic disease fail to
respond to this therapy (Rosenberg et al., 1988; Parkinson et
al., 1990).
Because of the toxicities associated with LAK/IL-2 therapy
and technical difficulties in generating TILs from certain solid
tumour specimens, several laboratories initiated studies on
lymphocytes infiltrating malignant effusions. Blanchard et al.
(1988) isolated malignant effusion-associated mononuclear
cells (MEMNCs), which upon activation with IL-2 exhibited
non-MHC-restricted lytic activity. Preferential cytotoxicity
for autologous tumour cells by CD3' MEMNCs has been
demonstrated in bulk cultures (Heo et al., 1988) and at the
clonal level (Fermni et al., 1985; loannides et al., 1991a).
Such cells have been demonstrated to recognise multiple
antigenic epitopes on autologous tumour cells (loannides et
al., 1991b).
Interleukin 1 (IL-1) plays a central role in immune re-
sponses by acting on different cell types and exhibiting mul-
tiple biological activities. Thus, IL-1 has been shown to
modulate the proliferation, maturation and biological activity
of B lymphocytes (Falkoff et al., 1984), T lymphocytes
(Mizel, 1982) and monocytes (Baxevanis et al., 1993a; Uhl et
al., 1989). IL-1 was also found to increase the expression of
specific genes (e.g. IL-2 receptor a-gene; Freimuth et al.,
1989) and to stimulate the synthesis of other cytokines [e.g.
IL-2, tumour necrosis factor (TNF) and IL-6; Schmidt &
Tocci, 1990] including itself (Dinarello et al., 1987). Recent
published data demonstrate that IL-1 is one of the main
co-stimulators for both naive and memory T-cell activation
(Plebanski et al., 1992), suggesting its involvement in the
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generation of effector (e.g. cytotoxic) T-cell types. In support
of this. IL-1 has been shown to inhibit tumour growth in
experimental animals (Forni et al.. 1989) and to potentiate T
cell-denrved tumour-specific responses (Cozzolino et al.,
1987). We report here that IL-l synergises with IL-2 for the
expansion of CD8+ cytotoxic T lymphocytes (CTLs) in
MEMNC cultures from malignant effusions (pleural and
ascites) from patients with advanced lung, breast and ovarian
cancer. This expansion was associated with increased produc-
tion of IFN-y in the cultures and resulted in increased levels
of cytotoxicity against autologous tumour cells. Thus selec-
tive outgrowth of IL-2-activated CD8+ malignant effusion-
derived CTLs in the presence of IL-lp may be useful in
adoptive cancer immunotherapy.
Materials and methods
Patients
Pleural or peritoneal (ascites) effusions were collected from
20 newly diagnosed patients with advanced or metastatic
cancer seen at the Surgery Clinic of the Hellenic Anticancer
Institute and at the Department of Oncology, 'Hippokration'
State Hospital, Athens. Patient characteristics are presented
in Table I. The age of the patients ranged from 30 to 79
years and patients had received no treatment with anti-cancer
agents within 1 month of sample collection.
Monoclonal antibodies
Fluorescein isothiocyanate (FHTC)-conjugated series of
monoclonal antibodies (MAbs) (anti-CD3, -CD14, -CD20,
-CD16, -CD25 and anti-HLA- DR), and phycoerythnn (PE)-
conjugated anti-CD4, -CD8, -CD25 and anti-HLA-DR MAbs
were purchased from Becton Dickinson (Mountain View,
CA, USA). Cells were incubated with the relevant MAb at
4°C for 30 min, and the antigen expression was analysed
using a FACScan (Becton Dickinson) (Baxevanis et at.,
1992).
Tissue culture media and reagents
RPMI-1640 medium, fetal calf serum (FCS) and Hanks'
balanced salt solution (HBSS) were purchased from Gibco
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Table I Patient characteristics and number of MEMNCs isolated from malignant
effusions
Patients Histology
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Small cell lung carcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Lung adenocarcinoma
Ovarian adenocarcinoma
Ovarian adenocarcinoma
Ovanan serous carcinoma
Ovarian adenocarcinoma
Ductal breast carcinoma
Ductal breast carcinoma
Malignant
effusions
Pleural
Pleural
Pleural
Pleural
Peritoneal
Peritoneal
Pleural
Pleural
Pleural
Peritoneal
Pleural
Pleural
Pk-ura
Pleural
Peritoneal
Peritoneal
PeTitoneal
Peritoneal
Peritoneal
Peritoneal
Lyrnocytes
x co a
180
250
160
170
150
75
70
230
500
170
220
75
60
125
190
330
50
125
250
375
MEMNC:7b
25.10
32.50
0.59
7.75
31.32
0.50
0.70
15.60
39.90
13.50
25.70
0.90
0.73
7.65
17.72
25.60
7.40
23.60
60.50
70.30
aLymphoctes (total numbers are given) were isolated from 500-2,000 ml ofpleural
or peritoneal (ascitic) fluids. IMEMNC-tumour cell ratio.
(Grand Island, NY, USA); Ficoll-Hypaque and Percoll from
Pharmacia Fine Chemicals (Uppsala, Sweden); L-glutamine,
and N-2-hydroxethylpiperazine-N-2-ethanesulphonic acid
(HEPES) from Sigma (St Louis, MO, USA); and [5CrJ-
sodium chromate from the Amersham Radiochemical Centre
(UK). Human recombinant IL-2 was a generous gift from
the Cetus Corporation (Emeryville CA, USA) [1 Cetus unit
(U) = 6 IU]. IL-lp (5 x 10 unitsmg-') was obtained from
Endogen (Boston, MA, USA). The complete medium con-
sisted of RPMI-1640, 10% FCS, 10mM HEPES, 2mM L-
glutamine and 100 gig ml-' gentamycin.
Preparation and culture ofeffusion cells
Specimens of pleural or peritoneal effusions (500-2,000 ml)
were obtained from the patients and centrifuged at 400 g for
10 min at 25'C to sediment cells. Cells were washed with
sterile HBSS and then layered on Ficoll-Hypaque cushions.
After centrifugation at 400 g for 20 min, tumour cells and
mononuclear cells were collected from the interface and
washed twice in HBSS. Tumour cells were separated from
mononuclear cells by centrifugation on discontinuous Percoll
density gradients as previously reported (Papamichail &
Baxevanis, 1992). In brief, cell suspensions were centrifuged
on differential Percoll gradients, and the tumour ceUs were
collected from the upper interface. The MEMNCs were col-
lected from the lower interface. Cells were washed with
HBSS and checked for viability with the aid of trypan blue
dye. Viability was always >90%. Tumour ceUls were used
either fresh or cryopreserved in liquid nitrogen in 90% FCS
plus 10% dimethylsulphoxide until ready for use in cultures
or as target cells in the cytotoxicity assays (see below), at
which time cells were carefully thawed, slowly diluted in
RPMI-1640, and washed. Tumours were accepted for assay if
viability was >80%. MEMNCs were diluted in complete
medium at a concentration of 2.5-5.0 x I0W cells ml-' in the
presence of 2.5-5.0 x 104 autologous tumour cells ml-' and
distributed in 2 ml aliquots in 24-well plates (Costar, Cam-
bridge, MA, USA) at 37C, in 5% carbon dioxide and 95%
humidity. After 3 days, IL-2 (100 U ml-'), alone or in com-
bination with IL-1p (l,00OUml-'), was added in cultures.
Two days later half of the volume of each well (1 ml) was
replenished with fresh complete medium containing the cyto-
kines and 2.5-5.0 x 104 autologous tumour cells. During the
first 2 weeks cells grew slowly; thereafter an accelerated
growth was observed. MEMNC cultures were passaged weekly
with 1 ml of fresh complete medium supplemented with fresh
cytokines. After 3-5 passages cultures were supplemented
once more with autologous tumour cells. Cells were kept
throughout the entire culture period in 24-well plates,
whereby the cell density at every passage was returned (using
fresh complete medium and cytokines) to 2.5-5.0 x
I05 cells ml 1.
Cvtotoxicity assai-
This was performed as reported previously (Baxevanis et al.,
1993b). Briefly, effector MEMNCs were resuspended at ap-
propriate concentration in complete medium and added in
100 gl aliquots to microtitre wells. r'Cr]sodium chromate-
labelled tumour targets (107 cells) were added in 100
aliquots at 5 x 103 cells to 5 x I0 effector cells in round-
bottom 96-well microplates (Costar). Culture plates were
incubated for 4 h at 5% carbon dioxide, 37C and 95%
humidity. After the end of incubation, 100 gil of supernatant
was removed from each well for isotope counting in a
gamma counter (Packard, Downers Grove, IL, USA). The
target cells were also incubated in medium alone and with
2% Triton X for estimations of spontaneous and maximum
release of isotope. All cultures were set up in triplicate. The
percentage specific release of 5'Cr was calculated according to
the formula
Speific 51CR rease (!
) -c.p.m. te -c.pm. spontaneous xl10
c.p.m maximum - c.pm. spontanwus
C}vtokine determination
Levels of IFN-y and TNF-a in the supernatants of bulk
cultures of MEMNCs were estimated using enzyme-linked
immunosorbent assay (ELISA) kits specific for IFN-y or
TNF-x (Genzyme, Boston, MA, USA) according to the
manufacturer's instruction. Quantitation of cytokine levels
was performed simultaneously in supernatants from cultures
incubated with IL-2 or IL-2 plus IL-lp collected and stored
within a period of 30 days.
Statistical analysis
Statistical analysis was performed by using the paired t test.
P-values less than 0.05 were considered significant.
Results
Variable proportions of MEMNCs and tumour cells were
recovered from pleural effusions (n = 11) and peritoneal
effusions (ascites) (n = 9). The ratio of MEMNCs to tumour
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cells ranged from 0.50 to 70.30 (Table I). Only in five of 20
individual samples did the number of tumour cells exceed the
number of lymphocytes. In the other 15 samples MEMNCs
substantially exceeded the tumour cells. By fluorescence
analysis, MEMNCs consisted of 73 ± 9% CD3+ T cells,
39 ± 7% CD3+CD4+ and 33 ± 7% CD3+CD8+ cells. Their
CD4 CD8 ratio was 1.18, which is within the range found in
peripheral blood (Hannet et al.. 1992). A significant propor-
tion of both CD3+ CD4+ and CD3+ CD8+ subsets was found
to bear the IL-2 receptor (33% and 39% ofCD4' and CD8+
subsets respectively). a marker of activated T cells. While the
number of CD20+ B cells and CD16+ natural killer (NK)
cells was low, with an average of 3 ± 2% and 6 ± 5% respec-
tively. normal proportions of CD14+ monocytes (14 ± 6%)
were found (Table II).
MEMNCs were cultured in the presence of IL-2
(100 U ml-') alone or supplemented with IL-1l
(1.000 U ml'). MEMNCs from all 20 patients increased in
number when cultured with IL-2 and reached maximum
propagation at an average of 39 ± 13 days with a mean
n-fold increase of 224 ± 122 ranging from 90 to 550 (Table
III). The vast majority of expanded MEMNCs were activated
T cells (CD3+ cells. 93 ± 5%0 CD3+ HLA-DR+ cells.
71 ± 12%; and CD3' CD25+ cells. 50 ± 8%0). Expansion of
MEMNCs was not appreciably augmented in cultures con-
taining IL-lp in addition to IL-2 (data not shown).
Flow cytometric analysis was used to determine the surface
phenotype of the expanded MEMNC cultures. A cytotoxity
assay was also performed in order to correlate MEMNC
phenotypes with cytotoxic function. By comparing the
phenotypes of IL-2-activated MEMNCs having autologous
tumour-specific cytotoxic activity with the phenotypes of
those having cytolytic activity against autologous and
allogeneic tumour target cells, significant differences were
observed in the percentages of cells expressing the CD4 and
CD8 antigens (Figures I and 2).
MEMNC cultures which exhibited preferential killing of
autologous tumour targets (Figure 1; MEMNCs from
patients 2, 6, 10, 11 and 16) consisted mainly (>68%) of
activated CD3+CD8+ T cells (Figure 2), whereas all other
cultures [i.e. those consisting of either CD3+ CD4+ T cells in
high numbers or mixtures of both T-cefl subsets (Figure 2)]
exhibited potent cytotoxicity against autologous and
allogeneic tumour cells (Figure 1).
A preferential outgrowth of CD3+ CD8+ cells was induced
in the same MEMNC cultures when these were initiated with
IL-2 (100Uml-') plus IL-lp (1,00OUml-') (mean value
from 20 cultures 68 ± 15% compared with 45 ± 24% in cul-
tures with IL-2 alone; P <0.02) (Figure 2). Preliminary
experiments revealed that doses of IL-1p lower than
1,000 U ml' remained without any statistically significant
effect (data not shown). The effect of IL-lp was much more
intense in MEMNC cultures, which in the presence of IL-2
alone yielded low percentages of CD3+ CD8+ cells [e.g.
MEMNCs from patients 9 and 18 cultured with IL-2 alone
yielded respectively 13% and 7% CD3+CD8+ cells (Figure
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Fgre Cytotoxicity of IL-2-activated MEMNCs against auto-
logous (a) and allogeneic (b) tumour cell targets. MEMNCs from
the indicated cancer patients were activated with IL-2 ( ) or
icity at the moment when the phenotype was determined (see
Figure 2). Increases in autologous tumour cytotoxicity in patients
no. 2. 6 10 11. 16 and 20 are not significant. In all other cases
P<0.05. Mean values from triplicates are shown. The s.d. in no
case excceeded 150. of the mean values and thus s.d. values are
omitted.
Table I Phenotype of freshly isolated MEMNCs
Percentages of cells
Patient CD3+ CD4+ CD3+ CD8+
no. CD3+ CD4+ CD25+ CD8+ CD25+ CDJ4+ CD20+ CD16+
1 75 38 17 32 10 10 3 6
2 72 40 10 30 13 7 3 12
3 52 29 9 20 5 25 5 20
4 83 60 13 25 12 10 2 3
5 66 32 15 35 17 14 10 15
6 71 36 12 39 13 20 1 1
7 68 38 17 29 10 17 6 9
8 81 40 6 42 20 10 2 5
9 77 37 16 26 12 15 6 9
10 82 50 20 32 15 3 2 9
11 86 35 9 49 22 6 1 2
12 75 35 13 41 15 13 6 7
13 72 36 15 36 10 20 5 3
14 83 49 22 40 17 5 1 2
15 66 42 7 26 6 22 1 3
16 75 50 9 29 9 20 5 2
17 58 28 12 30 12 26 6 5
18 70 39 15 30 10 12 3 9
19 82 32 13 50 25 12 2 2
20 92 30 16 32 13 20 7 7
Mean ±
s.d. 73±9 39±7 13±4 33±7 13±5 14±6 3±2 6±5628 C.N. BAXEV.ANIS et al.
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Figure 2 Percentages of CD8- (a) and CD4- (b) T cells within
MEMNCs cultured in iitro x-ith IL-2 ( _ ) or IL-2+IL-lx
( E ). Increases in CD3- CD8- cells were in all but six cases
(patients no. 2. 6. 10. 15. 16 and 20) statistically significant
(P<0.05).
2). whereas cells cultured with IL-2 + IL-1p yielded 620/o
(patient 9) and 43%o (patient 18) CD3 CD8+ cells (Figure
2)]. In contrast. only weak changes were noticed in cultures
which in the presence of IL-2 alone yielded high numbers of
CD3+ CD8+ cells (e.g. patients 2 and 10: Figure 2). The
expansion of CD3+CD4+ cells in the presence of IL-l1 and
IL-2 was associated with a decrease in the number of
CD3 CD4+ cells in the same cultures (Figure 2). The
preferential expansion of CD3+CD8+ cells in MEMNC cul-
tures initiated with IL-2 + IL-lp was correlated with higher
killing of autologous tumour cells (Figure 1). Increased
autotumour cytotoxicity was observed in cultures that in the
presence of IL-2 alone lysed both autologous and allogeneic
tumour cells. MEMNCs from patient 18 lysed autologous
and allogeneic tumour cells when cultured with IL-2 alone, at
40% and 65% respectively (Figure 1): when the same
MEMNCs were cultured with IL-2 + IL-Ip autologous
tumour cytotoxicity was increased up to 82%. whereas killing
of allogeneic tumour targets was markedly decreased (up to
20%) (Figure 2). Such changes were not observed in cultures
which exhibited a high level of autotumour cytotoxicity when
expanded with IL-2 alone (e.g. MEMNCs from patients 2
and 6) (Figure 1).
In a first attempt to analyse the mechanism(s) by which
IL-lp mediates its effect. we measured in the same cultures
the levels of IFN-y and TNF-a. which have been reported to
promote autologous tumour-specific cytotoxicity in TIL cul-
tures exogeneously added or endogeneously produced (Wang
et al.. 1989: Shimizu et al.. 1991: loannides et al.. 1991c). As
shown in Figure 3. there was a significant increase in IFN-y
levels in MEMNCs cultured with IL-2 and IL-lp (mean
value from 20 cultures: 340 ± 101 pg ml-') compared with
214± 108 pgml-' (P<0.01) produced in the same cultures
incubated with IL-2 alone. By' comparing the levels of
endogeneously produced IFN-y in MEMNC with IL-2 alone.
it becomes clear that these levels were increased in cultures
which displayed autologous tumour-specific cytotoxicity
(compare Figure 3 with Figure 1). thus confirming their role
in promoting CTL activity agaist autologous tumour cells.
Table III Phenotype of MEMNCs in long-tenn cultures with IL-2
Percentage of cells
Patient CD3- CD3- Time point
no. CD3- HLA-DR- CD25 of testing
1 97 86 45 35a (380)b
2 89 80 52 28 (110)
3 79 72 60 42 (200)
4 96 87 38 49 (350)
5 87 79 55 46 (160)
6 98 72 45 56 (120)
7 94 61 51 39 (90)
8 97 55 49 52 (130)
9 92 86 62 56 (390)
10 97 90 71 29 (100)
11 97 75 45 47 (300)
12 95 82 38 25 (200)
13 89 67 52 25 (270)
14 92 62 46 20 (130)
15 92 56 49 59 (550)
16 98 70 52 62 (320)
17 85 61 60 32 (150)
18 91 56 49 27 (100)
19 96 47 39 26 (150)
20 99 69 46 36 (290)
Mean +
s.d. 93 ± 5 71 ± 12 50 ± 8 39 ± 13 224 ± 122
ADavs in culture. bNumbers in parenthesis indicate expansion
index. Cultures w-ere maintained on a small scale expansion data
calculated by extrapolation. MEMNC expansion index calculated as
the ratio of the maximum number of lymphocytes in culture to the
number of lymphocytes at culture initiation.
In contrast to IFN-y levels. no significant change in the levels
of TNF-a was caused by the co-addition of IL-1p in
MEMNC cultures [mean values ± s.d. from 20 cultures
615 ± 152 pg ml-' (IL-2) vs 620 ± 117 pg ml[' (IL-2 + IL-1i)
(data not shown)]. Thus. increased endogenous production of
IFN-y seems to represent at least one of the signals through
which IL-lp enhances autologous tumour-specfic cytotoxi-
city in MEMNC cultures.
Discussion
Lymphocytes infiltrating solid tumours (TILs) or malignant
effusions (MEMNCs) have been repeatedly demonstrated to
efficiently lyse tumour cells in vitro upon activation with IL-2.
Such cytolytic responses can be specific. mediated solely
against autologous tumour cells. or non-specific. directed
against a panel of tumour cells (including also autologous
ones) and tumour cell lines (Baxevanis & Papamichail. 1994).
Thus it remains uncertain if autologous tumour-specific T
cells exist in certain tumours and not in others. Based upon
the in vitro demonstration of autotumour-specific CTLs in
the ascitic fluid but not in the tumour specimens of patients
with the same type of tumour (Heo et al.. 1988: loannides et
al.. 1991a). there are indications that it may be possible to
generate autologous tumour-specific cytotoxicity under ap-
propriate culture conditions. Therefore, much effort is now
being aimed at elucidating the regulatory function of numer-
ous cytokines associated with and potentially involved in the
induction of CTLs with specificity for autologous tumour cells
among TILs or MEMNCs. The elucidation of regulation of
anti-tumour cytolytic responses is important not only for
understanding the interaction of the immune system with
tumour cells but also for the potential development of
effective methods in cancer immunotherapy. Previous studies
from our laboratory have shown that exogenous IFN-'y acts
synergistically with IL-2 to promote autologous tumour-
reactive CTLs among TILs or MEMNCs (Papamichail &
Baxevanis. 1992) and to augment anti-tumour cytolytic re-
sponses in patients with cancer (Baxevanis et al.. 1993c).
Addition of TNF-a to TILs or MEMNCs cultured in IL-2
leads to preferential outgrowth of CD8+ cells, more
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Fres 3 Levels of IFN-y measured in the superatants of
MEMNC cultures incubated with IL-" (a) or IL-2+ IL-9 (b).
Superatants were collected at the time points when phenotype
and cvtotoxicitv were determined. Increases in IFN-2 levels were
stastically significant (P<0.05) in all but four cases (patient nos.
2. 10. 16 and 20). Results are means from triplicates. The s.d. was
negligible and thus is not shownm.
restricted target specificity and up-regulation of IL-2 receptor
on the ativated CD8' cells (Vaccarello et al., 1990; loannides
et al., 1991c). The addition of IFN-y or TNF-a to TILs
cultured in the presence of TNF-x and IL-2 significantly
augmented cytotoxicity against autologous tumour (Shimizu
et al., 1991).
In the present study we report a synergistic effect of IL-lB
with IL-2 for the preferential outgrowth of CD8+ CTLs from
lymphocytes infiltrating malignant effusions from patients
with metastatic cancer. This expansion resulted in increased
levels of cytotoxicity against autologous tumour cells and
was associated with increased production of IFN-y in the
MEMNC cultures. IL-lp alone was not capable of inducing
expansion or cytotoxicity in MEMNCs (data not shown). To
our knowledge our data provide novel evidence for the
involvement of IL-1p in the selective increase of autologous
tumour-reactive CD8+ CTLs among MEMNCs. since so far
synergy of IL-1 and IL-2 has been demonstrated only in the
generation of LAK activity (Crump et al.. 1989). whereby
IL-2 up-regulated the expression of IL-2 receptor on penr-
pheral blood mononuclear cells (PBMCs). Indirect eVidence
for the involvement of IL-1 in the generation of autologous
tumour CTLs was provided in a previous report (Osband et
al.. 1990). in which high levels of IL-1 in autologous lym-
phokine mixtures (ALMs) were shown to associate with suc-
cessful cellular adoptive immunotherapy in patients with
renal cell carcinoma using PBMCs activated in vitro with
ALMs (Osband et al.. 1990). Although not yet precisely
analysed. IL-lp seems to mediate its effect indirectly by
stimulating increased production of IFN-y. IFN-y is known
to be involved in CTL generation (Chen et al.. 1986: Gromo
et al.. 1987) and activation of CD8+ cells (Siegel. 1988).
Moreover, increased production of IFN-y could be measured
in IL-2 + TNF-a-stimulated TIL cultures, which exhibited
preferential cytotoxicity for autologous tumour cells (Wang
et al.. 1989). Thus IFN-y represents at least one of the signals
involved in the IL-lp-driven outgrowth of autologous
tumour-reactive CD8+ cells among MEMNCs. The in vivo
consequences of cellular adoptive immunotherapy using
MEMNCs activated in vitro by mixtures of IL-2 with IL-lp
are as yet unknown. IFN-y has direct tumoricidal activities
and also enhances expression of tumour MHC molecules and
tumour-specific antigens. thereby increasing the possibility of
immune recognition of tumour cells (Carrel et al.. 1985:
Stotter et al.. 1989). Attempts to treat solid human tumours
by the systemic administration of IFN-y (Garnick et al..
1988; Laszlo et al.. 1990) have been mostly unsuccessful
(although encouraging results in melanoma and sarcoma
patients have been reported: Lienad et al.. 1992). possibly
because the dose-limiting toxicities induced by IFN-y pre-
cluded delivery of effective cytokine concentrations to
tumour sites. Intratumoral production of IFN-y by the in
vitro-activated MEMNCs may be above levels that are
attainable with systemic administration and thus sufficient to
induce anti-tumour effects in vivo.
Collectively our data provide new information on the
selective outgrowth of autologous tumour-reactive CTLs
among MEMNCs. IL-lp has been shown to act synergis-
tically with IL-2 in this respect. with a parallel increase of
IFN-y levels in culture. Further studies are surely required to
better analyse the mechanism of action of an IL-2 plus IL-lp
combination on the growth. activation and functionality of
the autologous tumour-specific CD8+ CTLs. Information
obtained from such studies may improve the results of
clinical trials in cellular adoptive immunotherapy of cancer.
We wish to thank Miss Joanna Doukoumopoulou for her excellent
secretanal assistance.
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